The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GILD | +35.6% | +190.32% | +23.76% | +33,363% |
| S&P | +16.64% | +82.26% | +12.76% | +1,561% |
Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $7.96B | 5.2% |
| Gross Profit | $6.34B | 6.0% |
| Gross Margin | 79.65% | 0.6% |
| Market Cap | $152.28B | 32.3% |
| Market Cap / Employee | $8.96M | 0.0% |
| Employees | 17K | -3.4% |
| Net Income | $2.18B | 22.4% |
| EBITDA | $3.66B | 14.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.56B | -24.3% |
| Accounts Receivable | $4.91B | 11.2% |
| Inventory | 1.8K | 3.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $22.63B | -10.9% |
| Short Term Debt | $2.91B | 50.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 14.42% | 13.6% |
| Return On Invested Capital | 7.44% | -2.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $3.12B | 10.4% |
| Operating Free Cash Flow | $3.33B | 11.8% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 23.56 | 22.05 | 17.19 | 18.10 | -92.81% |
| Price to Book | 7.22 | 7.20 | 7.01 | 7.08 | 13.60% |
| Price to Sales | 4.92 | 4.83 | 4.79 | 5.22 | 29.01% |
| Price to Tangible Book Value | -15.63 | -16.23 | -19.13 | -32.13 | 189.95% |
| Price to Free Cash Flow TTM | 23.89 | 25.72 | 26.87 | 28.20 | 54.90% |
| Enterprise Value to EBITDA | 48.38 | 45.71 | 36.74 | 46.35 | 12.46% |
| Free Cash Flow Yield | 4.2% | 3.9% | 3.7% | 3.5% | -35.44% |
| Return on Equity | 32.5% | 33.3% | 40.5% | 40.5% | 1678.40% |
| Total Debt | $24.95B | $24.95B | $24.94B | $25.54B | -6.52% |
Here’s how CAR-T therapies did in their first full year on the market.
Declining sales increase the stakes for Gilead's most-promising R&D projects.
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
Celgene's and Gilead Sciences’ Q2 2017 results are fueling gains in their stock prices, but is one of these stocks doing better than the other?
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
